Purpose This study retrospectively evaluated overall survival (OS) by treatment of recurrent or metastatic uterine adenosarcoma including surgery, radiation, chemotherapy, and hormonal therapy and evaluated OS and progression-free survival (PFS) after 1st line systemic chemotherapy. Methods 78 patients with recurrent or metastatic adenosarcoma comprised the study population. The Kaplan-Meier ...

Mullerian adenosarcoma (MA) is a rare tumor variant with low malignancy potential and is reported to account for 8% of all uterine sarcomas. Cervical MAs are reported to occur in relatively younger patients with the mean age of 27 years, while those in the uterine corpus generally present in postmenopausal women. Due to the rarity of cervical MAs, optimal management for these patients (especial...

Sir: We read with interest the recent work by McCluggage et al. reporting the diagnostic utility of CD10 expression in distinguishing endometrial stromal lesions from other potential mimics, such as uterine smooth muscle neoplasms. CD10 is a cell-surface neutral endopeptidase detected in a variety of normal and neoplastic conditions. However, to the best of our knowledge, CD10 expression has ne...

•Uterine sarcomas are rare in adolescents. Adenosarcomas are even more rare. Uterine rupture, as a presentation is a rare entity.•It is hard to diagnose sarcomas preoperatively. It is still hard even postoperatively due to variable morphologic features.•Experience of the gynecopathologists and oncologic surgeons is the hallmark of the treatment option.

RATIONALE There is little knowledge regarding mullerian adenosarcoma and its metastasizing pattern. AIM Our objective was to evaluate the impact on the prognostic of the patient brought by tumor metastasizing to the retroperitoneum, to analyze the particularities of the treatment in such cases and to bring a significant change in the early therapeutic attitude to mullerian adenosarcomas. ME...

Purpose: Official guideline published and coordinated by the German Society of Gynecology and Obstetrics (DGGG). Due to their rarity and their heterogeneous histopathology uterine sarcomas remain challenging tumors to manage and need a multidisciplinary approach. To our knowledge so far there is no evidence-based guideline on the appropiate management of these heterogeneous tumors. Methods: Thi...

OBJECTIVE Ovarian adenosarcoma is a very rare tumour for which treatment options vary. We will consider the option of optimal cytoreductive surgery followed by adjuvant chemotherapy consisting of ifosamide (mesna) and adriamycin to prevent systemic metastasis, and will observe the role of serial CA-125 levels as a follow-up marker. CASE REPORT We report a case of ovarian adenosarcoma in a 38-...

Mullerian adenosarcoma following tamoxifen therapy is a rare condition. Our aim was to report the youngest patient in the literature with uterine mullerian adenosarcoma who was undergoing tamoxifen therapy for breast cancer. A premenopausal woman aged 38 years who was undergoing tamoxifen therapy for breast cancer, was admitted with symptoms of lower abdominal pain and irregular vaginal bleedin...

Introduction/Background Uterine sarcomas are rare tumors, representing 3 to 5% of malignant tumors the uterus. They characterized by a significant histopathological and clinical diversity. Their diagnosis is not very often made until analysis hysterectomy or myomectomy specimen, distinguishing between: carcinosarcoma; leiomyosarcoma; rhabdomyosarcoma; adenosarcoma; stromal sarcoma; und...

Background. Mullerian adenosarcoma with sarcomatous overgrowth (MASO) is a very rare variant of uterine sarcomas first described by Clement et al. as early as 1974. The presence of heterologous sarcomatous components is associated with aggressive biological behavior. Case Presentation. This is a case report of a 62-year female (P(2 + 0)) presenting with postmenopausal vaginal bleeding. Her preo...